公开(公告)号：US20210008178A1

公开(公告)日：2021-01-14

申请号：US16907985

申请日：2020-06-22

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Glenn PIERCE ,  Samantha TRUEX ,  Robert T. PETERS ,  Haiyan JIANG

IPC: A61K38/48 ,  A61K47/64 ,  A61K39/395 ,  C12N9/96 ,  A61K38/38 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61P7/04

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20190262429A1

公开(公告)日：2019-08-29

申请号：US16270302

申请日：2019-02-07

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Jennifer A. DUMONT ,  Susan LOW ,  Alan J. BITONTI ,  Glenn PIERCE ,  Alvin LUK ,  Haiyan JIANG ,  Byron MCKINNEY ,  Matt OTTMER ,  Jurg SOMMER ,  Karen NUGENT ,  Lian LI ,  Robert PETERS

IPC: A61K38/37 ,  A61K47/64 ,  C07K14/755 ,  A61K47/68 ,  C07K16/46

Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII: polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20240212861A1

公开(公告)日：2024-06-27

申请号：US18499693

申请日：2023-11-01

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Haiyan JIANG

IPC: G16H50/50 ,  A61K38/37 ,  A61K38/48 ,  C07K14/755 ,  C12N9/64 ,  G06N7/01 ,  G16C20/30 ,  G16C20/70 ,  G16H20/10 ,  G16H40/67

CPC classification number: G16H50/50 ,  A61K38/37 ,  A61K38/4846 ,  C07K14/755 ,  C12N9/644 ,  C12Y304/21022 ,  G06N7/01 ,  G16C20/30 ,  G16C20/70 ,  G16H20/10 ,  G16H40/67 ,  G16C20/90

Abstract: The present invention is directed to computer based pharmacokinetics systems, such as, web-based pharmacokinetics systems, and their use to predict a dose and a dosing interval for a patient in need of a clotting factor therapy.

公开(公告)号：US20230011438A1

公开(公告)日：2023-01-12

申请号：US17826932

申请日：2022-05-27

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Ekta Seth CHHABRA ,  Tongyao LIU ,  Robert T. PETERS ,  Haiyan JIANG

IPC: C07K14/755 ,  A61K47/62 ,  C07K16/00

Abstract: The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

公开(公告)号：US20210220476A1

公开(公告)日：2021-07-22

申请号：US17112280

申请日：2020-12-04

Applicant: Bioverativ Therapeutics Inc.

Inventor： Jennifer A. DUMONT ,  Susan LOW ,  Alan J. BITONTI ,  Glenn PIERCE ,  Alvin LUK ,  Haiyan JIANG ,  Byron MCKINNEY ,  Matt OTTMER ,  Jurg SOMMER ,  Karen NUGENT ,  Lian LI ,  Robert T. PETERS

IPC: A61K47/68 ,  A61K47/60 ,  A61K38/37 ,  C07K14/755 ,  G01N33/86

Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20180360982A1

公开(公告)日：2018-12-20

申请号：US15991629

申请日：2018-05-29

Applicant: Bioverativ Therapeutics Inc.

Inventor： Jennifer A. DUMONT ,  Susan LOW ,  Alan J. BITONTI ,  Glenn PIERCE ,  Alvin LUK ,  Haiyan JIANG ,  Byron MCKINNEY ,  Matt OTTMER ,  Jurg SOMMER ,  Karen NUGENT ,  Lian LI ,  Robert T. PETERS

IPC: A61K47/68 ,  A61K47/60 ,  G01N33/86 ,  A61K38/37 ,  C07K14/755

Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20230002828A1

公开(公告)日：2023-01-05

申请号：US17681435

申请日：2022-02-25

Applicant: Bioverativ Therapeutics Inc. ,  Puget Sound Blood Center

Inventor： Haiyan JIANG ,  Tongyao LIU ,  Sriram KRISHNAMOORTHY ,  Neil JOSEPHSON ,  Glenn PIERCE

IPC: C12Q1/6883 ,  A61K38/21 ,  A61K39/00 ,  A61K38/37 ,  C07K14/755 ,  A61K47/68

Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

公开(公告)号：US20220265780A1

公开(公告)日：2022-08-25

申请号：US17587941

申请日：2022-01-28

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Jennifer A. DUMONT ,  Susan LOW ,  Alan J. BITONTI ,  Glenn PIERCE ,  Alvin LUK ,  Haiyan JIANG ,  Byron MCKINNEY ,  Matt OTTMER ,  Jurg SOMMER ,  Karen NUGENT ,  Lian LI ,  Robert PETERS

IPC: A61K38/37 ,  A61K47/64 ,  A61K47/68 ,  C07K14/755 ,  C07K16/46

Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20220064622A1

公开(公告)日：2022-03-03

申请号：US17378200

申请日：2021-07-16

Applicant: Bioverativ Therapeutics Inc.

Inventor： Glenn PIERCE ,  Samantha TRUEX ,  Robert T. PETERS ,  Haiyan JIANG ,  Mark BRADER

IPC: C12N9/64 ,  C07K14/745 ,  C07K16/36

Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.

公开(公告)号：US20210023185A1

公开(公告)日：2021-01-28

申请号：US17032354

申请日：2020-09-25

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Glenn PIERCE ,  Samantha TRUEX ,  Robert T. PETERS ,  Haiyan JIANG

IPC: A61K38/48 ,  A61P7/04 ,  A61K47/64 ,  A61K38/38 ,  A61K39/395 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  C12N9/96

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.